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ABSTRACT (~ 150 words) 
Purpose 
We aimed to establish a magnetic resonance imaging (MRI) protocol for the sensitive and 
specific imaging of functional molecules with a pre-targeting strategy utilizing the 
streptavidin-biotin interaction. Membrane type-1 matrix metalloproteinase (MT1-MMP) was 
selected as the target molecule. 
Procedures 
The biotinylated polyamidoamine dendrimer (PAMAM)-based contrast agent 
(Bt-PAMAM-DTPA(Gd)) was prepared, and its proton relaxivity (r1) and affinity to 
streptavidin were evaluated. Tumor-bearing mice were pre-targeted with 
streptavidin-conjugated anti-MT1-MMP monoclonal antibody (mAb), 
streptavidin-conjugated negative control IgG, or saline and 3 days later were injected with 
Bt-PAMAM-DTPA(Gd) followed immediately by MRI for a period of 3 h. 
Results 
High r1 (15.5 L mmol-1 s-1) and 1.9-fold higher affinity than D-biotin were obtained. 
Significantly higher relative tumor signals were observed in mice pre-targeted with 
streptavidin-conjugated anti-MT1-MMP mAb (165% at 3 h vs. pre-administration) than with 
saline or streptavidin-conjugated negative control IgG (P < 0.0001). 
Conclusions 
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INTRODUCTION 
Magnetic resonance imaging (MRI), characterized by a remarkable spatial resolution, 
is a powerful tool for noninvasive morphologic diagnosis of diseases including cancer. 
Recently, the application of MRI to functional molecular imaging coupled with anatomical 
information has been explored. To realize functional molecular imaging by MRI, contrast 
agents are required that possess a high relaxation to produce high MR signals to compensate 
for the low intrinsic sensitivity of MRI [1] in addition to selectively accumulating in the 
targeting site. 
Gadolinium (Gd) chelates conjugated to macromolecules such as liposomes, micelles 
and dendrimers can give rise to enhanced proton relaxivities in comparison with simple, 
small molecule contrast agents such as Gd-diethylenetriamine pentaacetic acid (Gd-DTPA) 
[2-4]. This effect is due to a restriction in thermal flexibility leading to increased interactions 
between the Gd atom and surrounding water molecules [5-7]. Some groups have developed 
monoclonal antibody (mAb)-conjugated macromolecular contrast agents for imaging integrin 
vor human epidermal growth factor receptor type 2 (HER2) in tumors which 
successfully increased the tumor signal intensity by 15-30% [8, 9]. However, many 
researchers have failed to demonstrate in vivo functional molecular imaging using 
macromolecules conjugated with several Gd chelates and targeting moieties like antibodies 
and peptides because the pharmacokinetics of the targeting moieties were significantly altered 
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by the introduction of macromolecular contrast agents, which resulted in low target 
recognition and high accumulation of the labeling agent in non-targeted tissues [10, 11]. 
Furthermore, when antibody-conjugated macromolecular contrast agents are injected at a Gd 
dose (0.1 mmol Gd/kg) necessary for adequate imaging, excess antibody (on the order of 
milligrams per mouse) are typically administered, which leads to major limitations of cost 
and in vivo toxicity. 
Thus, in this study, to overcome these problems and to realize functional molecular 
MRI by a macromolecule-based contrast agent, we aimed to use a pre-targeting strategy that 
utilizes the high affinity interaction between streptavidin and biotin (Kd=10-15 M) [12]. In this 
pre-targeting method, the first step is to administer a streptavidin-conjugated target-specific 
antibody. In the second step, after selective accumulation of streptavidin-conjugated antibody 
in the targeted tissue and clearance of unbound targeting agent from the circulation, a 
biotin-bound imaging probe is injected. As the post-administration contrast agent, 
polyamideamine dendrimer (PAMAM) was selected as the base structure since it is 
structurally well-defined and functional moieties including biotins and Gd chelates for both 
targeting and signal emission functions can easily be attached to the large number of its 
surface amino groups. The pre-targeting strategy is expected to provide selective and 
effective accumulation of the PAMAM-based contrast agent to the targeted site and a high 
S/N ratio during the first hours following administration as has been observed in 
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radioimmunotherapy and radioimmunodetection [13-16], and to potentially lead to lower in 
vivo toxicity [17, 18]. 
Thus, in this paper we describe our efforts to establish a sensitive and specific in vivo 
MRI protocol for imaging functional molecules utilizing a pre-targeting strategy that 
combines a streptavidin-conjugated antibody with a PAMAM based contrast agent modified 
with biotins. As the targeted biomolecule, membrane type-1 matrix metalloproteinase 
(MT1-MMP) was selected. Since MT1-MMP is exclusively expressed in tumors and is 
closely associated with metastasis [19] and invasion [20], MT1-MMP is a potential imaging 
target for evaluation of tumor malignancy. 
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MATERIALS AND METHODS 
Synthesis of streptavidin-conjugated anti-MT1-MMP mAb 
Streptavidin-conjugated anti-MT1-MMP mAb and streptavidin-conjugated negative 
control IgG were synthesized according to a previously described method [14]. Briefly, 
EZ-Link® sulfosuccinimidyl-6-(biotinamido) hexanoate (sulfo-NHS-LC-biotin) (Pierce, Inc.) 
was added to a solution of anti-MT1-MMP mAb (113-5B7, Daiichi Fine Chemical Co.) in a 
molar ratio of 12:1. The mixture was gently stirred for 30 min at room temperature and then 
was purified with a diafiltration membrane (Amicon Ultra 4 (MWCO 30,000), Millipore Co.). 
A solution of biotinylated anti-MT1-MMP mAb was added to a solution of streptavidin (SAv; 
Pierce, Inc.) in a 1:3 molar ratio. The mixture was incubated for 1 h at 37 ˚C followed by 
purification twice by affinity chromatography using a HiTrap rProtein A column (GE 
Healthcare Bioscience). The eluate containing anti-MT1-MMP mAb-SAv was concentrated 
with a diafiltration membrane (MWCO 30,000), and the protein concentration was 
determined by the bicinchoninate (BCA) method. The purification was monitored by a size 
exclusion chromatograph using a 300×4.6-mm i.d. TSK-Gel Super SW 3000 column (Tosoh 
Co., Japan) eluted with phosphate buffer (0.1 M, pH 6.8) at a flow rate of 0.1 mL/min. 
Comparison of molecular mass standards (Oriental Yeast Co., Japan) of the absorbance at 
280 nm indicated that a peak at 30.3 min was consistent with the presence of the 210 kDa 
streptavidin-conjugated anti-MT1-MMP mAb. Furthermore, streptavidin-conjugated 
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anti-MT1-MMP mAb retained 81.3% immunoreactivity of the anti-MT1-MMP mAb, which 
was confirmed by flow cytometry. 
 
Synthesis of Bt-PAMAM-DTPA(Gd) 
EZ-Link® sulfo-NHS-LC-biotin was added to a solution of PAMAM (generation 4 (G4)) 
(Sigma Aldrich) in a molar ratio of 20:1. The mixture was stirred for 30 min at room 
temperature and then was applied to a diafiltration membrane (MWCO 10,000) to remove 
unbound biotins as well as to change the buffer to phosphate buffer (0.1 M, pH 9.0). After 
purification, the incorporation ratio of biotins conjugated to each dendrimer was measured 
using an EZTM Biotin Quantitation Kit (Pierce, Inc.). The biotinylated PAMAM was reacted 
with a 64-fold molar excess of 2-(p-isothiocyanatobenzyl)-diethylenetriaminepentaacetic acid 
(p-SCN-Bz-DTPA) (Macrocyclics) at 40˚C for 24 h. During the reaction, the pH was 
maintained at 9.0 with 1 N NaOH. An additional equal amount of p-SCN-Bz-DTPA was 
added after 24 h and the reaction was incubated for another 24 h at 40˚C. The resulting 
preparation was purified by diafiltration membrane (MWCO 10,000). After purification, the 
number of DTPAs incorporated into each G4 dendrimer was checked by chelate titration 
using ZnSO4 (indicator: 4-(2-pyridylazo)resorcinol, NH3/NH4+, pH 10) according to a 
previously described method with some modification [21]. Purified Bt-PAMAM-DTPA was 
mixed with GdCl3 (Sigma Aldrich) in citrate buffer (0.3 M, pH 5.0) for 2 h at 40˚C. The 
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excess Gd was removed by diafiltration membrane (MWCO 10,000) while simultaneously 
changing the buffer to PBS (0.1 M, pH 7.4). The number of Gd incorporated into a dendrimer 
was checked by separating the free Gd and Bt-PAMAM-DTPA(Gd) with diafiltration filter 
after labeling the Bt-PAMAM-DTPA with 153Gd and nonradioactive Gd. For comparison 
purposes, PAMAM-DTPA(Gd) containing one biotin (Bt1-PAMAM-DTPA(Gd)) was also 
prepared in a similar manner. 
 
Stability of Bt-PAMAM-DTPA(Gd) in mouse plasma 
153Gd-labeled Bt-PAMAM-DTPA(Gd) was prepared by reacting 
Bt-PAMAM-DTPA(Gd) with 153Gd (1 Ci, PerkinElmer Japan Co., Osaka, Japan) and 
non-radioactive Gd in 0.3 M citrate buffer at pH 5.0 for 2 h at 40˚C. 153Gd labeled 
Bt-PAMAM-DTPA(Gd) (30 L) was added to mouse plasma collected from female C3H/He 
mice (270 L), and the plasma samples were incubated at 37˚C for 0, 3, and 24 h. After 
incubation, aliquots of the samples were drawn, and radioactivity was analyzed by 
size-exclusion chromatography with a PD-10 column (GE Healthcare Bioscience) using 
saline as eluent. 
 
Affinity of Bt-PAMAM-DTPA(Gd) for streptavidin 
Competition assays of 125I-(3-iodobenzoyl)norbiotinamide (125I-IBB), a radiolabeled 
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biotin derivative synthesized as reported previously [22], were performed by incubating 
streptavidin (Pierce, Inc.; 400 L, 2 g/mL), 125I-IBB (50 L, 5 Ci), and various 
concentrations of Bt-PAMAM-DTPA(Gd), Bt1-PAMAM-DTPA(Gd), and D-biotin (Nacalai 
Tesque, Kyoto, Japan) (50 L, 10-8~10-4 M) in PBS (0.1 M, pH 7.4) for 60 min at 37˚C. At 
the end of the incubation, the mixture was applied to a size exclusion column with a 
Sephadex G-50 Fine (GE Healthcare Bioscience), followed by measurement of the 
radioactivity from the column eluent (containing macromolecules) with a NaI well-type 
scintillation counter (1470WIZARD, PerkinElmer Japan Co.). Nonspecific binding was 
determined in the presence of 10 mg/mL D-biotin. The 50% inhibitory concentrations (IC50s) 
were determined from displacement curves of the percent inhibition of 125I-IBB binding vs. 
the inhibitor concentration. 
 
Preparation of tumor-bearing animals 
Female C3H/He mice (5 weeks old), supplied by Japan SLC Co. (Hamamatsu, Japan), 
were housed under a 12-h light/12-h dark cycle and were given free access to food and water. 
The animal experiments in this study were conducted in accordance with institutional 
guidelines and were approved by the Kyoto University Animal Care Committee, Japan. 
FM3A mouse breast carcinoma cells were supplied by the Health Science Research 
Resources Bank (Osaka, Japan). They were cultured in DMEM medium (Nissui 
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Pharmaceutical Co.) supplemented with 10% fetal bovine serum at 37˚C in a humidified 
atmosphere containing 5% CO2 and 95% air and had a 10.6-h doubling time. 
FM3A cells were suspended in 0.01 M PBS (pH 7.4) followed by subcutaneous 
inoculation into the right hind leg of the mouse (5 × 106 cells/100 L/mouse) [23]. The tumor 
volume was estimated by (length)×(width)2/2 [24] over a 10-day tumor growth period. The 
average size of the tumors was 213 ± 82 mm3 on the MR imaging study day. The expression 
of MT1-MMP in FM3A cells and tumor tissues was confirmed by western blotting and 
immunohistochemistry [25]. 
 
Magnetic Resonance Imaging 
MRI was performed using a clinical 1.5 Tesla MR scanner (MAGNETOM Symphony 
Sonata, Siemens). All T1-weighted MR images were acquired with a multislice spin-echo 
pulse sequence. MRI data were analyzed using the ImageJ software. 
Phantom study 
Solutions of Gd-DTPA (Sigma Aldrich) and Bt-PAMAM-DTPA(Gd) were prepared 
with a Gd concentration in the range of 10 to 500 M in vials with an inner diameter of 15 
mm followed by the MR scan using a knee coil (20.5 cm in diameter) at 20˚C. To obtain 
proton relaxivity (r1) for samples, spin-echo images were obtained using a sequence with 
TR=500, 1000, 1500, and 2000 msec and with TE=15 msec. The imaging parameters were as 
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follows: field-of-view, 256×128 mm; matrix, 256×128; slice thickness, 7 mm; number of 
average, 3. 
In vivo study 
Mice (n=4) bearing FM3A tumors in the right thigh received streptavidin-conjugated 
anti-MT1-MMP mAb (50 g/100 L in saline) via tail vein. Three days later, 
Bt-PAMAM-DTPA(Gd) (0.1 mmolGd/kg, 100 L in PBS (0.1 M, pH 7.4), i.v.) was injected 
followed by data acquisition by MRI at several time points over a 3-h post-injection period 
under sodium pentobarbital (50 mg/kg, i.p.) anesthesia. All MR images were obtained using a 
hand-made round surface coil (5.5 cm in diameter) fixed by a custom constructed coil holder. 
The imaging parameters were as follows: TR/TE, 300/5.2 msec; field-of-view, 128×96 mm; 
matrix, 256×192; slice thickness, 1.5 mm; number of average, 3. MRI studies were also 
conducted as above on FM3A tumor bearing mice (n=3) pre-treated with saline (100 L) or 
streptavidin-conjugated negative control IgG (50 g/100 L in saline). The signal intensity 
was calculated by drawing a region of interest around the tumor, muscle in the contralateral 
hind limb, and kidneys. The relative signal intensity in each tissue was defined as the signal 
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Unpaired Student’s t test was used to evaluate the significance of differences of r1 
between Bt-PAMAM-DTPA(Gd) and Gd-DTPA. To compare the time courses of relative 
signal intensity in the tumor and kidneys and tumor/muscle (T/M) signal ratios among 
Bt-PAMAM-DTPA(Gd) pre-targeted by streptavidin-conjugated anti-MT1-MMP mAb, 
streptavidin-conjugated negative control IgG, and saline, two-way repeated measures ANOVA 
with post-hoc analysis by the Tukey-Kramer test was performed. Differences at the 95% 
confidence level (P < 0.05) were considered significant. 
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RESULTS 
Characterization of Bt-PAMAM-DTPA(Gd) 
Bt-PAMAM-DTPA(Gd) was synthesized in four steps from PAMAM in a yield of 
63%. PAMAM was conjugated to 9.9 ± 1.3 biotins and 43.6 ± 1.9 DTPAs, which were 
quantitatively coordinated to Gd. Bt1-PAMAM-DTPA(Gd) containing 1.0 ± 0.1 biotin and 
47.6 ± 2.2 DTPAs on PAMAM dendrimer was also synthesized. The 153Gd-labeled 
Bt-PAMAM-DTPA(Gd), which was incubated with mouse plasma for 24 h, did not release 
any low molecular weight metabolites or free radiometals (Fig. 1).  
The competitive binding assay revealed that all of the contrast agents inhibited the 
binding of 125I-IBB to streptavidin in a dose-dependent manner (Fig. 2). The IC50s for 
Bt-PAMAM-DTPA(Gd), Bt1-PAMAM-DTPA(Gd), and D-biotin were 32 ± 31, 1390 ± 1220, 
and 60 ± 45 nM, respectively, demonstrating that Bt-PAMAM-DTPA(Gd) had about 1.9- and 
43.2-fold higher affinity to streptavidin than D-biotin and Bt1-PAMAM-DTPA(Gd). 
 
MR imaging study (Phantom study) 
The in vitro T1-weighted MR images with Bt-PAMAM-DTPA(Gd) and Gd-DTPA are 
shown in Fig. 3a. Water and PBS were used as baselines. With the same Gd concentration, 
the signals with Bt-PAMAM-DTPA(Gd) were higher compared to Gd-DTPA. The 
longitudinal relaxation rate (1/T1) vs. the concentration of Gd for both contrast agents are 
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shown in Fig. 3b with good linear fits (R2 = 1.00 and 0.99 for Bt-PAMAM-DTPA(Gd) and 
Gd-DTPA, respectively). Calculated r1 values (L mmol-1 s-1) for Bt-PAMAM-DTPA(Gd) and 
Gd-DTPA were 15.5 ± 1.1 and 3.6 ± 0.1, respectively, which shows that the proton relaxivity 
of Bt-PAMAM-DTPA(Gd) was 4.3-fold higher than that of Gd-DTPA (P < 0.0001). 
 
MR imaging study (in vivo study) 
Figure 4a (coronal) and 4b (transaxial) show in vivo T1-weighted MR images of 
tumor-bearing mice before and at 5 min and 180 min after injection of 
Bt-PAMAM-DTPA(Gd) following pre-treatment with streptavidin-conjugated 
anti-MT1-MMP mAb (MT1-MMP), streptavidin-conjugated negative control IgG (Negative 
Control), or saline (Saline). In the MT1-MMP group, the most intense signal was observed in 
the margin of the tumor, as compared with the tumor core, over the 180-min period. The 
relative signal intensity (rSI) in the tumor and the relative T/M ratio were strongly enhanced 
just after administration of Bt-PAMAM-DTPA(Gd) and were highly maintained for 3 h after 
the contrast agent injection as well as the rapid clearance from the circulation (Fig. 4c, d). 
These signals were significantly greater than those from the Negative Control group (P < 
0.05 (at 44 and 55 min), P < 0.01 (at 2 and 3 h)). In the Saline group, Bt-PAMAM-DTPA(Gd) 
readily disappeared from the circulation and mainly accumulated in the kidneys. Though the 
relative signal intensity in the tumor also increased (190%) just after administration of 
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Bt-PAMAM-DTPA(Gd), it decreased to the basal level (115%) within 3 h (Fig. 4c). A slightly 
higher tumor signal was obtained in the Negative Control group than in the Saline group only 
3 h after injection of Bt-PAMAM-DTPA(Gd) (P < 0.01). The time-dependent change of 
relative T/M ratios was similar to that of the relative signal intensity in the tumor (Fig. 4d). 
The time-dependent change of relative signal intensity in the kidneys was very similar in all 
three groups (Fig. 4e). 
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DISCUSSION 
In this study, we accomplished visualization of MT1-MMP by MRI using a 
pre-targeting method with a PAMAM-based contrast agent (Bt-PAMAM-DTPA(Gd)) which 
possesses high proton relaxivity and high affinity to streptavidin. For future applications, this 
pre-targeting method based on the interaction between biotin and streptavidin is promising 
for the detection of functional molecules, such as biomarkers in tumors like MT1-MMP, by in 
vivo MRI. 
Although several macromolecular contrast agents have been developed for functional 
molecular imaging with MRI using a mAb or peptide as the targeting moiety, these attempts 
have been largely unsuccessful because the macromolecular contrast agents, such as an 
antibody attached to a dendrimer, have a poorer targeting ability and slower pharmacokinetics 
in the circulation than the targeting moiety alone, which leads to an inadequately low S/N 
ratio for several days post-injection [10, 11]. Thus, we focused on a pre-targeting strategy 
whose effectiveness in elevating the S/N ratio shortly after injection has been well 
documented in the field of radioimmunotherapy [13, 26]. In the pre-targeting strategy, high 
affinity between the pre- and post-administered agents is required; thus, the affinity of a 
post-administered biotinylated contrast agent to streptavidin needed to be evaluated. In this 
study, Bt-PAMAM-DTPA(Gd) containing approximately 10 biotins in the structure showed 
43.2- and 1.9-fold higher affinity to streptavidin compared with Bt1-PAMAM-DTPA(Gd) 
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containing only one biotin per dendrimer and D-biotin, respectively, which suggests a 
multivalent effect of Bt-PAMAM-DTPA(Gd) binding to streptavidin. Zhu et al. recently 
reported the MRI of functional molecules by a pre-targeting approach [27]; however, the 
authors failed to show a significant tumor image probably because of the small number of 
biotins per dendrimer (~4 biotins per dendrimer). Therefore, in a pre-targeting method where 
a macromolecule is used as the post-administered agent, it is essential that an optimal number 
of biotins on the macromolecule is evaluated. 
In the streptavidin-conjugated anti-MT1-MMP mAb-treated group, MR signals in the 
tumor and T/M ratios were highly maintained following Bt-PAMAM-DTPA(Gd) 
administration compared with the saline-treated group, which suggests that the tumor 
accumulation of Bt-PAMAM-DTPA(Gd) depended on the pre-targeted 
streptavidin-conjugated anti-MT1-MMP mAb. Furthermore, MR signals in the tumor and 
T/M ratios were also significantly higher in the streptavidin-conjugated anti-MT1-MMP 
mAb-treated group than those in the negative control, which suggests that the accumulation 
of Bt-PAMAM-DTPA(Gd) was primarily specific for MT1-MMP. The slightly significant 
difference in the relative tumor signal was shown between negative control and saline group 
is probably caused in part by passive accumulation of the pre-targeted 
streptavidin-conjugated antibody as a macromolecule due to an enhanced permeability and 
retention effect [28]. 
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Previously, to determine the optimal interval between injections of 
streptavidin-conjugated anti-MT1-MMP mAb and Bt-PAMAM-DTPA(Gd), the 
biodistribution of 125I-labeled streptavidin-conjugated anti-MT1-MMP mAb was evaluated in 
C3H/He mice bearing FM3A mouse breast carcinoma [14]. From consideration of the high 
accumulation of streptavidin-conjugated antibody in the tumor and the high tumor to blood 
ratio at 72 h, we adopted this time as the interval between pre- and post-administrations in 
this study. Recently, some reports have shown that clearing agents (e.g. galactosylated 
biotin-albumin conjugate) can readily (within a few hours) clear surplus streptavidin 
conjugated antibody in the circulation to the liver where the complex is metabolized and 
excreted without loss of the biotin binding sites in the tumor [29-31], thereby shortening the 
interval between injections. In the future, by taking advantage of this type of strategy, we can 
establish an optimal protocol for MT1-MMP imaging for clinical applications. 
Dendrimers are a class of highly branched spherical polymers, with a variety of 
properties, such as chemical structure, size, molecular weight and functional groups that can 
be easily manipulated at the molecular level through their synthesis. The pharmacokinetics of 
the dendrimer is susceptible to control with its generation number such that it may be highly 
bioavailable, an important consideration for a variety of applications, especially in the 
biomedical field [32]. Here, PAMAM dendrimer was chosen as the base structure of the 
contrast agent for post-administration. PAMAM dendrimer (G4) with an ethylene diamine 
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core has a molecular weight of 14,215 Da and possesses 64 amino groups on the surface of 
the molecule [33]. In this study, 10 biotins and 44 Gds for specific targeting and sensitive 
imaging were introduced onto the dendrimer. An in vitro MR study showed that the relaxivity 
of Bt-PAMAM-DTPA(Gd) was 4.3-fold higher than Gd-DTPA, which indicates the 
effectiveness of Bt-PAMAM-DTPA(Gd) as a contrast agent with high proton relaxivity as 
expected because of slow tumbling rates and a short water residence time [2, 5].  
The post-administered contrast agent in a pre-targeting study should satisfy the 
following two requirements besides specific affinity to pre-administered streptavidin: rapid 
blood clearance and low nonspecific accumulation in the tumor. It has been reported that a 
PAMAM (G4) dendrimer is quickly excreted via glomerular filtration primarily during the 
first pass (the blood  phase half-life: 2.5 min,  phase half-life: 35 min [34]), and not via the 
bile pathway. In addition, these dendrimers exhibit no measurable leakage from normal blood 
vessels because of their moderate size (ca 6 nm) [2, 34-37], which leads to low nonspecific 
accumulation in the tumor caused by passive accumulation based on an enhanced 
permeability and retention effect. PAMAM (G4)-based MR contrast agents can be effective 
as imaging probes, as supported by the experimental data that showed low MR signals 
observed in the tumors of the saline pre-targeted group while intense signals were observed in 
the kidneys after the acute disappearance of Bt-PAMAM-DTPA(Gd) from the circulation. 
As mentioned above, in the case of antibody-conjugated dendrimer-based contrast 
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agents, excess antibodies (on the order of milligrams per mouse) are typically administered 
when injected at a Gd dose (0.1 mmol Gd/kg) necessary for adequate imaging, which leads to 
major limitations of cost and toxicity. On the other hand, our pre-targeting strategy could 
control the amount of injected streptavidin-conjugated antibody by corresponding to the 
targeted molecule (about 50 g per mouse for MT1-MMP), which would be useful for 
reducing the cost and toxicity of the imaging process. 
In the application of dendrimers in vivo, cytotoxicity is often a major issue. To date, as 
has been widely demonstrated for other polycations, dendrimers bearing amino termini 
display concentration- and commonly generation-dependent cytotoxicity [38] and potent 
hemolytic activity [39]. These effects could be attributable to the electrostatic interactions of 
the positively charged dendrimer with the negatively charged cell membrane under 
physiological pH. Nevertheless, Bt-PAMAM-DTPA(Gd) used in this study was negatively 
charged due to modifications of the amino termini to bind biotin and DTPA such that it could 
be acceptable in vivo. This assertion is supported by a report that PAMAM dendrimers 
bearing carboxylate termini display dramatically lower toxicity to cells [40]. We also plan to 
acetylate or succinylate the free amino groups to further reduce the positive charge of the 
complexes if needed to decrease toxicity and hemolytic activity. The rapid excretion of 
Bt-PAMAM-DTPA(Gd) via glomerular filtration should alleviate adverse effects such as 
nephrogenic systemic fibrosis [41] derived from released Gd, as compared with 
 - 23 -
macromolecular contrast agents which have slow elimination pharmacokinetics [11, 42], 
although further analysis of the cytotoxicity is needed. 
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CONCLUSIONS 
The pre-targeting method utilizing the specific interaction between streptavidin and 
biotin enabled the visualization of MT1-MMP expressing tumors by 1.5 T MRI with high 
S/N ratios during the first hours following administration of a contrast agent, 
Bt-PAMAM-DTPA(Gd). The results suggest that this method may be beneficial to diagnose 
tumor malignancy in a clinical setting. In future work, this method could be applied to the 
imaging of a variety of pathologic functional molecules expressed on cell surface. 
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Size exclusion analysis of 153Gd-labeled Bt-PAMAM-DTPA(Gd) radioactivity after 
incubation at 37˚C in mouse plasma. The error bars represent standard deviations. 
 
Figure 2 




(a) In vitro T1-weighted MR measurements of different concentrations of Gd (micromolar) 
from Gd-DTPA and Bt-PAMAM-DTPA(Gd) in PBS at 1.5 T. PBS and water were used as 
references. These images show that at all concentrations, the signals are greater for 
Bt-PAMAM-DTPA(Gd) than for Gd-DTPA. 
(b) Longitudinal relaxation rate (1/T1) vs. the concentration of Gd from Gd-DTPA (crosses) 
and Bt-PAMAM-DTPA(Gd) (circles) in PBS at 1.5 T are presented with good linear fits 
(R2>0.99). The r1 value for Bt-PAMAM-DTPA(Gd) was 4.3-fold higher than for 
Gd-DTPA. 
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Figure 4 
(a, b) In vivo T1-weighted MR images of C3H/He mice before and at 5 min and 180 min after 
injection of Bt-PAMAM-DTPA(Gd) following  pre-treatment with streptavidin-conjugated 
anti-MT1-MMP mAb (MT1-MMP), streptavidin-conjugated negative control IgG (Negative 
control), or saline (Saline). The coronal (a) and transaxial (b) images are shown. Arrows or 
dotted squares indicate the tumor site. Enlarged images of the dotted square regions are also 
shown. 
(c-e) The dynamic change of signal intensity in the tumor by Bt-PAMAM-DTPA(Gd) (c) and 
relative tumor to muscle ratios (d) following pre-treatment with streptavidin-conjugated 
anti-MT1-MMP mAb (MT1-MMP, circles), streptavidin-conjugated negative control IgG 
(Negative control, squares), or saline (Saline, crosses). (e) The dynamic change of signal 
intensity in the kidney for each animal group. *P < 0.05, §P < 0.01 vs. Negative Control; #P 
< 0.01 vs. Saline; †P < 0.01 Negative Control vs. Saline 




